The price-to-earnings ratio for Quest Diagnostics, Inc (NYSE: DGX) is above average at 20.34x, Company’s 36-month beta value is 0.90.Analysts have differing opinions on the stock, with 8 analysts rating it as a “buy,” 1 as “overweight,” 10 as “hold,” and 0 as “sell.”
The public float for DGX is 111.06M, and currently, short sellers hold a 1.84% ratio of that floaft. The average trading volume of DGX on December 20, 2024 was 831.25K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
DGX) stock’s latest price update
The stock of Quest Diagnostics, Inc (NYSE: DGX) has increased by 0.18 when compared to last closing price of 151.25.Despite this, the company has seen a loss of -2.92% in its stock price over the last five trading days. zacks.com reported 2024-12-04 that Quest Diagnostics introduces Health Coaching on questhealth.com, helping individuals take control of their health.
DGX’s Market Performance
Quest Diagnostics, Inc (DGX) has experienced a -2.92% fall in stock performance for the past week, with a -5.98% drop in the past month, and a -0.96% drop in the past quarter. The volatility ratio for the week is 2.38%, and the volatility levels for the past 30 days are at 1.77% for DGX. The simple moving average for the last 20 days is -4.47% for DGX’s stock, with a simple moving average of 4.01% for the last 200 days.
Analysts’ Opinion of DGX
Many brokerage firms have already submitted their reports for DGX stocks, with Morgan Stanley repeating the rating for DGX by listing it as a “Overweight.” The predicted price for DGX in the upcoming period, according to Morgan Stanley is $172 based on the research report published on December 17, 2024 of the current year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see DGX reach a price target of $185, previously predicting the price at $175. The rating they have provided for DGX stocks is “Buy” according to the report published on December 10th, 2024.
Robert W. Baird gave a rating of “Outperform” to DGX, setting the target price at $182 in the report published on October 23rd of the current year.
DGX Trading at -3.25% from the 50-Day Moving Average
After a stumble in the market that brought DGX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -8.35% of loss for the given period.
Volatility was left at 1.77%, however, over the last 30 days, the volatility rate increased by 2.38%, as shares sank -6.07% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +1.68% upper at present.
During the last 5 trading sessions, DGX fell by -2.92%, which changed the moving average for the period of 200-days by +19.38% in comparison to the 20-day moving average, which settled at $158.60. In addition, Quest Diagnostics, Inc saw 9.89% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DGX starting from PREVOZNIK MICHAEL E, who sale 35,146 shares at the price of $163.07 back on Nov 29 ’24. After this action, PREVOZNIK MICHAEL E now owns 38,478 shares of Quest Diagnostics, Inc, valued at $5,731,302 using the latest closing price.
Doherty Catherine T., the EVP, Regional Businesses of Quest Diagnostics, Inc, sale 33,103 shares at $162.99 during a trade that took place back on Nov 27 ’24, which means that Doherty Catherine T. is holding 68,412 shares at $5,395,484 based on the most recent closing price.
Stock Fundamentals for DGX
Current profitability levels for the company are sitting at:
- 0.14 for the present operating margin
- 0.32 for the gross margin
The net margin for Quest Diagnostics, Inc stands at 0.09. The total capital return value is set at 0.09. Equity return is now at value 12.66, with 5.67 for asset returns.
Based on Quest Diagnostics, Inc (DGX), the company’s capital structure generated 0.48 points at debt to capital in total, while cash flow to debt ratio is standing at 0.22. The debt to equity ratio resting at 0.92. The interest coverage ratio of the stock is 6.86.
Currently, EBITDA for the company is 1.73 billion with net debt to EBITDA at 3.49. When we switch over and look at the enterprise to sales, we see a ratio of 2.42. The receivables turnover for the company is 6.93for trailing twelve months and the total asset turnover is 0.59. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.25.
Conclusion
In a nutshell, Quest Diagnostics, Inc (DGX) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
